



Express Mail No. EV335858089US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider and Jamal

Confirmation No.: 1583

Serial No.: 09/305,084

Art Unit: 1642

Filed: May 4, 1999

Examiner: Canella, Karen A.

For: Cancer Treatment With Endothelin
Receptor Antagonists

Attorney Docket No: 5914-080-999

RECEIVED
DEC 19 2003
TECH CENTER 1600/2900

FEE TRANSMITTAL SHEET

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$724.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID		PRESENT EXTRA		RATE		ADDIT. FEE	
TOTAL	22	MINUS	20	2	x 9	\$		x 18	\$ 36.00
INDEP.	16	MINUS	8	8	x 43	\$		x 86	\$ 688.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						\$		\$	0.00
TOTAL						\$	OR	TOTAL	\$ 724.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.
A copy of this sheet is enclosed.

Date: December 11, 2003

Respectfully submitted,

Laura A. Coruzzi
Laura A. Coruzzi
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

30,742
(Reg. No.)

Enclosure



EXPRESS MAIL NO.: EV335858089US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider and Jamal

Confirmation No.: 1583

Application No.: 09/305,084

Group Art Unit: 1642

Filed: May 4, 1999

Examiner: Canella, Karen A.

For: Cancer Treatment With Endothelin
Receptor Antagonists

Attorney Docket No.: 5914-080-999

RECEIVED
DEC 19 2003
FEDERAL CENTER 1600/2900

SUPPLEMENTAL REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents,
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed November 17, 2003, please enter the following amendments and consider the remarks made below in connection with the above-identified application. Also submitted herewith are: (a) an Amendment Fee Transmittal Sheet (in duplicate) and a (b) table disclosing a non-exhaustive list of ETB selective antagonists as Appendix A.

12/17/2003 EAREGAY1 00000119 161150 09305084

01 FC:1201 688.00 DA
02 FC:1202 36.00 DA